Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01125150 · ClinicalTrials.gov registry record

Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia

A clinical trial of Hyperinsulinemia and Acanthosis Nigricans, sponsored by Henry Ford Health System.

Completed
Registry status
9
Enrollment target
1
Study location

NCT01125150 is a study of Hyperinsulinemia and Acanthosis Nigricans that has completed, run by Henry Ford Health System. The registered enrollment target is 9 participants, below the 254-participant average among 5 other Hyperinsulinemia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01125150, a study of Hyperinsulinemia and Acanthosis Nigricans, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
9 participants
Enrollment target
1
Study location

Study Summary

Acanthosis Nigricans is skin disease that associated with hyperinsulinemia. Clinical is velvety hyperpigmented plaques on neck, axilla, groin. If hyperinsulinemia is improved by treated with oral metformin and/ or diet control, acanthosis nigricans would be improved as well. Hyperpigmented plaques will be changed. We assess objective measurement by using spectroscopic and colorimetric analysis.

Interventions

  • DRUG Metformin
  • BEHAVIORAL Dietary Modification

Study Locations (1)

Michigan

  • Department of Dermatology, NEW CENTER ONE - Detroit

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2009-02
Est. Completion 2012-06

Sponsor

Henry Ford Health System

234 total trials

What the Registry Record Tells You About NCT01125150

The ClinicalTrials.gov registry entry for NCT01125150 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 5 other Hyperinsulinemia trials with a reported enrollment target (96% lower). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hyperinsulinemia appearing as the primary indexed condition, and to 2 interventions - of which Metformin is the first listed.

NCT01125150 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT01125150 about?

NCT01125150 is a clinical study titled "Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia". Acanthosis Nigricans is skin disease that associated with hyperinsulinemia. Clinical is velvety hyperpigmented plaques on neck, axilla, groin. If hyperinsulinemia is improved by treated with oral metformin and/ or diet control, acanthosis nigricans would be improved as well. Hyperpigmented plaques w...

What is the current status of trial NCT01125150?

This trial is currently completed. The enrollment target is 9 participants. The study started on 2009-02. Estimated completion is 2012-06.

What conditions does trial NCT01125150 study?

This clinical trial studies the following conditions: Hyperinsulinemia, Acanthosis Nigricans, Spectroscopic Analysis.

What interventions are being tested in trial NCT01125150?

The interventions under investigation include: Metformin (DRUG), Dietary Modification (BEHAVIORAL).

Who is sponsoring clinical trial NCT01125150?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01125150 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hyperinsulinemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.